Progesterone for the prevention of preterm birth: a narrative review
Abstract
Preterm birth is the main cause of perinatal mortality in the world. Despite interventions, preterm rates keep rising. Several studies have assessed the utility of progesterone as a preventive intervention in high risk patients. This narrative review aims to assess the current evidence regarding prevention of preterm birth with progesterone. A search in different databases between 2000 - 2015 of clinical trial studies, meta–analysis and clinical practice guidelines was conducted. Mesh terminology was used. Relevance of studies was determined by using PRISMA and CONSORT checklists, and quality of evidence was established according to the Canadian Task Force on Preventive Health Care criteria. 32141 studies were found, 17 were included for this review. Meta–analysis: 2, clinical trials: 8, systematic reviews: 2, secondary analysis of clinical trials: 2, decision analysis: 1, clinical practice guidelines: 2. It was concluded that progesterone, when used in single pregnancy in high risk patients (cervicometry <20mm, history of preterm birth), reduces its presentation.Downloads
References
OMS. Objetivos de Desarrollo del Milenio. [Internet]. Disponible en: http://www.who.int/topics/millennium_development_goals/es/ Consultado: 19 de septiembre de 2015.
Wax, J., Cartin, A., Pinette, M. Biophysical and Biochemical Screening for the Risk of Preterm Labor. Clin Lab Med. 2010;(30):693–707
Simmons, L., Rubens, C., Darmstadt, G., Gravett, G. Preventing Preterm Birth and Neonatal Mortality: Exploring the Epidemiology, Causes, and Interventions. Semin Perinatol. 2010; 34:408-15
World Health Organization (WHO). Born to soon: The Global Action Report on Preterm Birth. 2012. [Internet] Disponible en: http://www.who.int/pmnch/media/news/2012/preterm_birth_report/en/ [Consultado: 26 de agosto de 2015]
Tan, M., To, M. Recent advances in the prevention and management of preterm birth. F1000Prime Reports. 2015; (7):40
Winer, N., Bretelle, F., Senat, M., Bohec, C., Deurelle, P., Perrotin, F., et. al. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2015; 212:485.e1-10.
World Health Organization (WHO). Preterm births per 100 births. 2010. [Internet] Disponible en: http://www.who.int/
pmnch/media/news/2012/2010_pretermbirthsper100births.pdf (Consultado: 20 de mayo de 2016)
Clínica de la mujer. Guía de práctica clínica amenaza de parto pretérmino. 2014. [Internet] Disponible en http://www.clinicadelamujer.com.co/files/parto_pretermino.pdf (Consultado: 27 de agosto de 2015)
Palencia, A. Parto prematuro. Sociedad Colombiana de Pediatría. [Internet] Disponible en: https://scp.com.co/precop/precop_files/modulo_9_vin_4/Precop_9-4-B.pdf (Consultado: 15 de septiembre de 2015)
Preterm Birth. March of Dimes Peristat. [Internet] Disponible en: http://www.marchofdimes.org/Peristats (Consultado: 15
de septiembre de 2015)
Departamento Administrativo Nacional de Estadística (DANE). Nacimientos 2013. [Internet] Disponible en http://www.dane.gov.co/index.php/poblacion-y-demografia/nacimientos-y-defunciones/118-demograficas/estadisticas-vitales/4647-nacimientos-2013 (Consultado: 21 de mayo de 2016)
Andersen, H. Use of fetal fibronectin in women at risk for preterm delivery. Clinical Obstetrics and Gynecology. 2000;
(4):746-58
Goldenberg, R., Goepfert, A., Ramsey, P. Biochemical markers for the prediction of preterm birth. Am J Obstet Gyneacol.
; 192:S36-46.
Goldenberg, R., Culhane, J., Jams, J., Romero, R. Epidemiology and causes of preterm birth. Lancet. 2008; 371:75-84.
López, J., Sánchez, H., Gutiérrez, M., Gámez, C. Fibronectina fetal y longitud cervical como predictores tempranos de parto pretérmino. Ginecol Obstet Mex. 2011; 79(6):337-43. [Internet] Disponible en: http://www.medigraphic.com/pdfs/ginobsmex/gom-2011/gom116b.pdf (Consultado: 5 de septiembre de 2015)
Markham, K., Klebanoff, M. Prevention of Preterm Birth in Modern Obstetrics. Clin Perinatol. 2014; 41: 773–85
Manzanares, S., López, M., Redondo, P., Garrote, A., Molina, F., Carrillo, M., et. al. Amenaza de parto prematuro. Valor de la cervicometría y la fibronectina. Actualización Obstetricia y Ginecología. 2009. [Internet] Disponible en: http://www.hvn.es/servicios_asistenciales/ginecologia_y_obstetricia/ficheros/07appvalordelacervicometriasmanzanares.pdf (Consultado:26 de agosto de 2015)
Brown J., Thieman, G., Shad, D., Fleisher A., Bohen, F. Transabdominal and transvaginal endosography: evaluation of the cervix and lower uterine segment in pregnancy. Am J Obstet Gynecol. 1986; 155:721-6.
Werner, E., Han, C., Pettker, C., Buhimschi, C., Copel, J., Funai E., et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2011; 38:32–7
Conde, A., Romero, R., Nicolaides, K., Chaiworapongsa, T., O’Brien, J., Cetingoz, E., et al. Vaginal progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Gynecol. 2013; 208:42.e1-18.
Alfirevic, Z., Owen, J., Carreras, E., Sharp, A., Szychowskis, J., Goya, M. Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix. Ultrasound Obstet Gynecol. 2013; 41:146–51.
Hall, J. Fisiología femenina antes del embarazo y hormonas femeninas. En Hall, J., 12ª ed. Guyton y Hall. Tratado de Fisiología médica. España. Elsevier Saunders. 2011; 987–1002
Norwitz, E., Caughey, A. Progesterone supplementation and the prevention of Preterm birth. Rev Obstet Gynecol. 2011;
(2):60–72
Canadian Agency for Drugs and Technologies in Health. Vaginal Micronized Progesterone Capsules for the Prevention of
Miscarriage and Preterm Birth: A Review of the Clinical Evidence.[Internet] Disponible en: http://www.ncbi.nlm.nih.gov/
pubmedhealth/PMH0071425/ (Consultado: 12 de septiembre de 2015)
Rai, P., Rajaram, S., Goel, N., Ayalur, R., Agarwal, R., Mehta, S. Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology and Obstetrics. 2009;104:40–3
Ransom, C., Murtha, A. Progesterone for preterm birth prevention. Obstet Gynecol Clin N Am. 2012; 39:1–16
Meis, P., Klebanoff, M., Thom E., Dombrowski, M., Sibai, B., Moawad, A., et. al. Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate. N Engl J Med. 2003; 348(24):2379-85
Heyborne, K. Allshouse, A., Carey, C. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women? Am J Obstet Gynecol 2015.
Fonseca, E., Celik, E., Parra, M., Singh M., Nicolaides, K. Progesterone and the Risk of Preterm Birth among Women with a Short Cervix. N Engl J Med 2007; 357:462-9.
Romero, R., Nicolaides, K., Conde, A., Tabor, A., O’Brien, J., Cetingoz, E., et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012; 206:124.e1-19.
Dodd, J., Jones, L., Flenady, V., Cincotta, R., Crowther, C. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth (Review). Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD004947. DOI: 10.1002/14651858.CD004947.pub3.
Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella: Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206:376-86.
Prediction and prevention of preterm birth. Practice Bulletin No. 130. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120: 964–73.
Keeler, S., Kiefer, D., Rochon, M., Quinones, J., Novetsky, A., Rust, O. A randomized trial of cerclage vs. 17 α hydroxyprogesterone caproate for treatment of short cervix. J. Perinat. Med. 2009; 37:473–79
Maher, M., Abdelaziz, A., Ellaithy, M., Bazeed, M. Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone. Acta Obstet Gynecol Scand. 2013; 92:215–22
Hassan, S., Romero, R, Vidyadhari, D., Fusey, S., Baxter, J., Khandelwal, M., et al. Vaginal progesterone reduces the rate
of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; 38:18–31
Rode, L., Klein, K., Nicolaides, K., Krampl, E., Tabor, A. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011; 38:272–80
Klein, K., Rode, L., Nicolaides, K., Krampl, E., Tabor A. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 2011; 38:281–87
Brizot, M., Hernandez, W., Liao, A., Bittar, R., Francisco, R., Krebs, V., et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2015; 213:82.e1-9
Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) Statement. [Internet] Disponible en:
http://www.prisma-statement.org/ (Consultado: 20 de octubre de 2015)
Consolidated Standards of Reporting Trials (CONSORT) Statement. [Internet] Disponible en: http://www.consort-statement. org/ (Consultado: 20 de octubre de 2015)
Manterola, C., Zavando, D. Cómo interpretar los “Niveles de Evidencia” en los diferentes escenarios clínicos. Rev. Chilena de Cirugía. 2009; 61(6):582-95
Canadian Task Force on Preventive Health Care. [Internet] Disponible en: http://canadiantaskforce.ca/ (Consultado: 20 de
mayo de 2016)
.png)
